Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

PLSE 10.30.2024

Full Press ReleaseSEC FilingsOur PLSE Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium
  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - Pulse Biosciences’ Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

Recent Filings

  • 01.14.2025 - 8-K Current report
  • 01.13.2025 - 4 Statement of changes in beneficial ownership of securities

AddsAndrea Natale, M.D. as a medical advisor, joining existing advisorsVivek Reddy, M.D. andJacob Koruth, M.D.

MIAMI--(BUSINESS WIRE)--Oct. 30, 2024--Pulse Biosciences, Inc.(Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field AblationTM (nsPFATM) technology, today announced the appointment ofDavid Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology.Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisorsVivek Reddy, M.D. andJacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for thePulse Biosciencesnano-PFA 360 Cardiac Catheter.

“I am inspired by the potential of nano-PFA and the unique catheter design of the 360 catheter that is already demonstrating the ability to isolate pulmonary veins with ease and speed,” said Dr.David Kenigsberg, Chief Medical Officer of Electrophysiology ofPulse Biosciences. “I was impressed when I saw the 360 catheter in use and am excited to work with Pulse to deliver robust clinical data with the 360, which I believe will substantially advance the treatment of atrial fibrillation. I look forward to supporting this team through its next phase of clinical development.”

Dr. Kenigsbergis a practicing cardiac electrophysiologist with a passion for treating atrial fibrillation over his career. He is the founder ofFlorida Heart Rhythm Specialistsand Ft.Lauderdale Heart& Rhythm Surgical Center. He has been the Medical Director of theElectrophysiology LabatHCA Westside Medical CenterinPlantation, Florida, since 2007. He has published numerous scholarly articles in peer-reviewed medical journals. He has advised in the development and has been the primary investigator/co-investigator in a myriad of clinical trials involving ablation tools.Dr. Kenigsbergis a fellow of theAmerican College of Cardiologyand theHeart Rhythm Society. He is the President of theFlorida Chapter of the American Collegeof Cardiology and sits on theAmerican College of Cardiology Board of Governors.

“This is an exciting time in electrophysiology as pulsed field ablation technologies are becoming widely adopted and advancing the standard of care. I am excited to support the Pulse team in the clinical efforts for the 360 catheter,” added Dr.Andrea Natale.

Dr.Andrea Nataleis the Executive Medical Director of theTexas Cardiac Arrhythmia Instituteat St. David’s Medical Center inAustin, Texas, and the National Medical Director of Cardiac Electrophysiology for HCA Healthcare. A dedicated researcher and pioneer, Dr.Andrea Natalefocuses on innovative advances in the treatment of atrial fibrillation. He has been, and continues to be, involved in many first-in-human trials to test investigational devices, recently performing the first pre-clinical and clinical studies to develop and perfect ablation catheters utilizing a novel, groundbreaking ablation energy source known as irreversible electroporation.

Burke T. Barrett, President and Chief Executive Officer ofPulse Biosciencesconcluded, “We are significantly strengthening our team with the addition of these renowned physicians who will contribute to generating high quality clinical data that demonstrates the clinical performance profile of the 360 catheter. I want to thank Drs. Reddy and Koruth for their significant contributions in the pre-clinical and clinical evaluations of the 360 catheter to date.”

About Pulse Biosciences®

Pulse Biosciencesis a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFATM technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.Pulse Biosciencesis now headquartered inMiami, Floridaand maintains its office inHayward, California.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks ofPulse Biosciences, Inc.inthe United Statesand other countries.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241030976724/en/

Investors:Pulse Biosciences, Inc.Burke T. Barrett, President and CEOIR@pulsebiosciences.com

Or

Gilmartin GroupPhilip Trip Taylor415.937.5406philip@gilmartinir.com

Source:Pulse Biosciences, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com